<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630483</url>
  </required_header>
  <id_info>
    <org_study_id>Medipol Hospital 17</org_study_id>
    <nct_id>NCT04630483</nct_id>
  </id_info>
  <brief_title>Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery</brief_title>
  <official_title>The Effect of Different Anesthesia Methods on the Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medipol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medipol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer is a major cause of morbidity and mortality worldwide. Despite the use of surgery in&#xD;
      an attempt to cure the majority of solid tumors, metastasis from residual cancer cells still&#xD;
      remains a major cause of morbidity and mortality. General anesthesia and surgical stress&#xD;
      during surgery suppress the immune response by directly affecting the immune system or by&#xD;
      activating the hypothalamic-pituitaryadrenal axis and the sympathetic nervous system. The aim&#xD;
      of our prospective observational study was to assess the value of neutrophil-to-lymphocyte&#xD;
      ratio and platelet-to-lymphocyte ratio regarding outcome underwent cancer surgery. Primary&#xD;
      aim is to assess the preoperative and postoperative values of inhalational anesthesia vs&#xD;
      total intravenous anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer is a major cause of morbidity and mortality worldwide. Despite the use of surgery in&#xD;
      an attempt to cure the majority of solid tumors, metastasis from residual cancer cells still&#xD;
      remains a major cause of morbidity and mortality. As is the case with most cancers,&#xD;
      loco-regional recurrence and distant metastases are all too common, even after successful&#xD;
      surgical treatment and adjuvant therapy. Cancer metastasis is a complex process in which&#xD;
      cancer cells evade the immune system. Cancer cells gain the ability to proliferate, migrate,&#xD;
      and invade adjacent tissues, and together with angiogenesis, these capabilities facilitate&#xD;
      the successful metastasis of cancer.&#xD;
&#xD;
      General anesthesia and surgical stress during surgery suppress the immune response by&#xD;
      directly affecting the immune system or by activating the hypothalamic-pituitaryadrenal axis&#xD;
      and the sympathetic nervous system. Along with surgical stress, blood transfusion,&#xD;
      hypothermia, and postoperative pain, anesthetics are associated with immunosuppression during&#xD;
      perioperative periods because anesthetics/analgesics have direct suppressive effects on&#xD;
      cellular and humoral immunity. In general anesthesia, it is suggested that inhalational&#xD;
      anesthesia (INHA) such as sevoflurane and isoflurane may modulate antimetastatic immunity by&#xD;
      inhibiting NK cell cytotoxicity and inhibit T helper cell proliferation. This could&#xD;
      potentially be unfavorable for cancer survival. In contrast, propofol-based total intravenous&#xD;
      anesthesia (TIVA) is suggested to have anti-inflammatory features and to be advantageous&#xD;
      compared with INHA by promoting the activation of T-helper cells, decreasing matrix&#xD;
      metalloproteinases, and not suppressing NK cell activity to the same extend as INHA. The&#xD;
      immunological impact of the anesthetic agents may thus influence clinical measures including&#xD;
      overall mortality and postoperative recovery. Recently, some readily available parameters,&#xD;
      originated from routine complete blood count (CBC), have been investigated as potential&#xD;
      biomarkers with mixed results and no consensus so far regarding its accuracy and clinical&#xD;
      usefulness: neutrophil-to-lymphocyte ratio (NLR), monocyte-to lymphocyte ratio (MLR),&#xD;
      platelet-to-lymphocyte ratio (PLR), and mean platelet volume-to-platelet count (MPV/PC)&#xD;
      ratio.&#xD;
&#xD;
      The aim of our prospective observational study was to assess the value of NLR and PLR ratio&#xD;
      regarding outcome underwent cancer surgery. Primary aim is to assess the preoperative and&#xD;
      postoperative values of inhalational anesthesia vs total intravenous anesthesia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Months</target_duration>
  <primary_outcome>
    <measure>The value of NLR and PLR ratio</measure>
    <time_frame>Average 6 months, through study completion</time_frame>
    <description>Primary aim is to assess the preoperative and postoperative values of inhalational anesthesia vs total intravenous anesthesia.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cancer</condition>
  <condition>Urologic Neoplasms</condition>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Group I: INHA</arm_group_label>
    <description>Inhalational anesthesia (INHA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II: TIVA</arm_group_label>
    <description>Total intravenous anesthesia (TIVA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>INHA</intervention_name>
    <description>NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values</description>
    <arm_group_label>Group I: INHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TIVA</intervention_name>
    <description>NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values</description>
    <arm_group_label>Group II: TIVA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Scheduled for elective cancer surgery (urology, general surgery, gynecologic)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) classification I-II&#xD;
&#xD;
          -  Scheduled for elective cancer surgery (urology, general surgery, gynecologic) under&#xD;
             general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary sepsis and/or septic shock with an underlying condition&#xD;
&#xD;
          -  Active infection such as severe peritonitis, pancreatitis, or trauma&#xD;
&#xD;
          -  Long-term ICU stay&#xD;
&#xD;
          -  Preexisting immunodeficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Bahadir Ciftci, Asisst prof, MD</last_name>
    <phone>+905325034428</phone>
    <email>bciftci@medipol.edu.tr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul Medipol University Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Bagcilar</state>
        <zip>34070</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bahadir Ciftci, MD</last_name>
      <phone>+905325034428</phone>
      <email>bciftci@medipol.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>MÃ¼rsel Ekinci, MD</last_name>
      <phone>+905067137596</phone>
      <email>drmurselekinci@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Kim R. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Rev. 2017 Mar;36(1):159-177. doi: 10.1007/s10555-016-9647-8. Review.</citation>
    <PMID>27866303</PMID>
  </reference>
  <reference>
    <citation>Kim R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J Transl Med. 2018 Jan 18;16(1):8. doi: 10.1186/s12967-018-1389-7. Review.</citation>
    <PMID>29347949</PMID>
  </reference>
  <reference>
    <citation>Djordjevic D, Rondovic G, Surbatovic M, Stanojevic I, Udovicic I, Andjelic T, Zeba S, Milosavljevic S, Stankovic N, Abazovic D, Jevdjic J, Vojvodic D. Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Mean Platelet Volume-to-Platelet Count Ratio as Biomarkers in Critically Ill and Injured Patients: Which Ratio to Choose to Predict Outcome and Nature of Bacteremia? Mediators Inflamm. 2018 Jul 15;2018:3758068. doi: 10.1155/2018/3758068. eCollection 2018.</citation>
    <PMID>30116146</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medipol University</investigator_affiliation>
    <investigator_full_name>Bahadir Ciftci</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cancer surgery</keyword>
  <keyword>Anesthesia</keyword>
  <keyword>Neutrophil-to-lymphocyte ratio</keyword>
  <keyword>Platelet-to-lymphocyte ratio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

